Tenpoint Therapeutics has raised Series A funds of $70m to develop engineered cell-based therapies to reverse vision loss.
Seed investors F-Prime Capital, Sofinnova Partners and British Patient Capital led the financing round, with Qiming Venture Partners USA, Eight Roads and the UCL Technology Fund among others taking part.
The company will utilise the financing to develop a regenerative medicine platform that could substitute multiple types of cells that are destroyed by inherited and age-linked ocular ailments.
Tenpoint Therapeutics CEO Eddy Anglade stated: “Cell-based therapeutics represent an ideal modality for degenerative ocular diseases since most vision loss results from damaged or missing tissue.
“At Tenpoint, we are focused exclusively on the eye and on harnessing recent advances in regenerative biology to advance our therapies as we work to change the future for people with vision loss by addressing its underlying causes.”
The company is currently developing methods to create tailored ocular cell types ex vivo and in vivo.
F-Prime and Sofinnova Partners, the first investors of Tenpoint, backed the initial operational and technological growth of the company.
Sofinnova Partners managing partner Graziano Seghezzi stated: “Tenpoint stands out in the realm of regenerative medicine, with an innovative approach that could ultimately provide a transformative cure to many causes of blindness for millions of patients around the world.”
Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva.
Editorial content is independently produced and follows the highest standards of journalistic integrity. Topic sponsors are not involved in the creation of editorial content.
Source link
#Tenpoint #raises #funds #develop #cell #therapies #vision #loss
